|1.||Sadeh, J: 2 articles (07/2012 - 03/2010)|
|2.||Stryszak, P: 2 articles (07/2012 - 03/2010)|
|3.||Bond, Richard: 2 articles (04/2009 - 08/2007)|
|4.||Langdon, Ronald B: 1 article (10/2013)|
|5.||Ma, Xuewen: 1 article (10/2013)|
|6.||Khalilieh, Sauzanne: 1 article (10/2013)|
|7.||Kamtchoua, Thierry: 1 article (10/2013)|
|8.||Stryszak, Paul: 1 article (10/2013)|
|9.||Seiberling, Michael: 1 article (10/2013)|
|10.||Gaga, M: 1 article (07/2012)|
|1.||Asthma (Bronchial Asthma)
07/01/2012 - "To investigate the safety and efficacy of SCH527123, a selective CXCR2 receptor antagonist, in patients with severe asthma and increased number of neutrophils in sputum. "
07/01/2012 - "In a randomized, double-blind, parallel study, patients with severe asthma and sputum total cell count < 10 × 10(6) /g and neutrophils > 40% were randomized to SCH527123, 30 mg daily PO (n = 22) or placebo (n = 12) for 4 weeks. "
07/01/2012 - "The SCH527123 is safe and reduces sputum neutrophils in patients with severe asthma. "
|2.||Chronic Obstructive Pulmonary Disease (COPD)
03/01/2010 - "SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease. "
06/01/2012 - "In vivo results verified that SCH-527123 treatment decreased tumor growth and microvessel density when compared with vehicle-treated tumors. "
06/01/2012 - "Importantly, these preclinical studies showed that the combination of SCH-527123 and oxaliplatin resulted in a greater decrease in cell proliferation, tumor growth, apoptosis, and angiogenesis that was superior to single-agent treatment. "
04/01/2009 - "Treatment of melanoma cells with SCH-479833 or SCH-527123 also inhibited tumor growth. "
04/01/2009 - "For in vivo studies, A375SM cells were implanted subcutaneously into athymic nude mice followed by administration of SCH-479833, SCH-527123, or hydroxypropyl-beta-cyclodextrin (20%) orally for 21 days and their effect on tumor growth and angiogenesis was evaluated. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2012 - "SCH-527123 showed concentration-dependent antiproliferative effects in HCT116, Caco2, and their respective IL-8-overexpressing variants colorectal cancer cell lines. "
06/01/2012 - "The aim of this study was to investigate whether the CXCR2 antagonist, SCH-527123, inhibits colorectal cancer proliferation and if it can sensitize colorectal cancer cells to oxaliplatin both in vitro and in vivo. "
|5.||Fibroblast Growth Factor 7
|8.||Arachidonic Acid (Vitamin F)
|9.||Interleukin-7 (Interleukin 7)